| |
| Issue |
Title |
| |
| No 9 (2025) |
Experience with the use of the generic drug ivacaftor + tezacaftor + elexacaftor and ivacaftor in an adult patient with cystic fibrosis in clinical practice |
Abstract
PDF (Rus)
|
|
Z. M. Merzhoeva, V. V. Gaynitdinova, S. N. Avdeev |
| |
| No 20 (2024) |
Distribution of values of indicators of minimum suppressive concentrations of antibiotics in relation to gram-negative bacterial strains isolated from cystic fibrosis |
Abstract
PDF (Rus)
|
|
R. R. Galieva, O. V. Kondratenko, O. N. Gavrilova, D. A. Kokorev, P. V. Bochkareva |
| |
| No 20 (2023) |
Prevalence of antimicrobial-resistant Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis |
Abstract
PDF (Rus)
|
|
A. V. Lyamin, M. O. Zolotov, O. V. Kondratenko, E. A. Maksimova, D. D. Ismatullin, P. V. Bochkareva |
| |
| No 20 (2023) |
Characteristics of CF patients over 18 years of age in the Republic of Tatarstan |
Abstract
PDF (Rus)
|
|
G. R. Shakirova, E. D. Gizatullina |
| |
| No 4 (2023) |
Effectiveness of lumacaftor/ivacaftor in 1-year therapy of cystic fibrosis in adult patients |
Abstract
PDF (Rus)
|
|
S. A. Krasovskiy, R. U. Kagazezhev, O. G. Zonenko, D. F. Sergienko, N. S. Butyugina, M. Y. Gushchin |
| |
| No 18 (2022) |
Influence of exogenous and endogenous factors on lung function in children and adolescents with cysistic fibriosis with genetic variant F508DEL in homozygous state |
Abstract
PDF (Rus)
|
|
V. V. Shadrina, E. G. Furman, M. A. Starinova, A. Yu. Voronkova, V. D. Sherman, E. K. Zhekaite, E. I. Kondratyeva |
| |
| No 18 (2022) |
Mannitol therapy for children with cystic fibrosis: efficacy and safety |
Abstract
PDF (Rus)
|
|
O. I. Simonova, Yu. V. Gorinova, O. V. Vysokolova, M. A. Mukhina, E. E. Yakushina |
| |
| No 4 (2022) |
The use of targeted therapy lumacaftor/ivacaftor in patients with cystic fibrosis |
Abstract
PDF (Rus)
|
|
A. G. Chermensky, T. E. Gembitskaya, A. V. Orlov, V. R. Makhmutova |
| |
| No 4 (2022) |
Characteristics of mukoviscisidosis in the southern regions of Russia |
Abstract
PDF (Rus)
|
|
E. I. Kondratieva, S. V. Trishina, A. V. Yurieva, N. V. Komlev, V. A. Tanaga, V. A. Terentiev, A. Yu. Voronkova, E. L. Amelina, A. V. Chernyak, S. A. Krasovskiy, V. Yu. Brisin, M. M. Khachiyan, E. V. Vodovozova, E. A. Enina, L. N. Ledeneva, E. T. Yagubyants, M. M. Chepurnaya |
| |
| No 4 (2022) |
Clinical and functional control of mucolytic therapy in children with cystic fibrosis |
Abstract
PDF (Rus)
|
|
O. I. Simonova, S. G. Bystrova, Yu. V. Gorinova |
| |
| No 16 (2021) |
Hypertonic saline in the treatment of patients with cystic fibrosis in Russian Federation |
Abstract
PDF (Rus)
|
|
E. I. Kondatyeva, V. D. Sherman, V. V. Shadrina |
| |
| No 16 (2021) |
Features of the course and eradication of multidrug-resistant Pseudomonas aeruginosa infection in cystic fibrosis: clinical case |
Abstract
PDF (Rus)
|
|
E. I. Kondratyeva, E. V. Loshkova, E. D. Nikolaeva, M. M. Khachiyan, G. N. Yankina |
| |
| No 18 (2017) |
INFLUENCE OF NEONATAL SCREENING FOR CYSTIC FIBROSIS BY THE EXAMPLE OF PATIENTS OF THE MOSCOW REGION |
Abstract
PDF (Rus)
|
|
V. D. Sherman, E. I. Kondratieva, A. Y. Voronkova, N. Y. Kashirskaya, L. A. Shabalova, V. S. Nikonova, E. K. Zhekaite, S. I. Kutsev |
| |
| 1 - 13 of 13 Items |
|
